Onco-Summaries: Daily Oncology Updates at a Glance
06/10/2026
Firmonertinib failed to demonstrate statistically significant PFS benefit in 1L EGFR Exon 20ins NSCLC (Ref)
ArriVent announced a program update from the Phase 3 FURVENT trial evaluating firmonertinib (EGFR-TKI) as first-line treatment for patients with EGFR exon 20 insertion-mutant NSCLC. While the study did not meet its primary endpoint of progression-free survival (PFS) by blinded independent central review (BICR), regimen demostrated encouraging secondary efficacy signals and a manageable safety profile
Endpoint | Firmonertinib 240 mg | Firmonertinib 160 mg | Chemotherapy | Interpretation |
Median PFS (BICR) | 11.0 mo | 8.4 mo | 9.5 mo | Primary endpoint missed; PFS benefit did not reach statistical significance |
HR: 0.75; p=0.0654 | ||||
Confirmed ORR (BICR) | 60% | 35% | 33% | Substantially higher response rate with 240 mg dose |
Median PFS (Investigator-Assessed) | 11.1 mo | 8.3 mo | 7.1 mo | Secondary efficacy endpoint favored 240 mg dose |
Overall Survival | Early favorable trend | Not reported | Reference | OS data immature; follow-up ongoing |
Grade ≥3 TEAEs | 52% | 53% | 55% | Comparable overall high-grade toxicity across arms |
Grade ≥3 TRAEs | 26% | 22% | 40% | Lower treatment-related toxicity than chemotherapy |
Safety Profile | No new safety signals | No new safety signals | Expected profile | Safety findings consistent with prior experience |
Comments